Diabetic Investor finds the timing of Animas's price decline interesting when you consider that were was a flurry of insider selling in May. This by coincidence was about the same time the JNJ rumors were hot and heavy. Diabetic Investor never believed the JNJ rumors were serious as Animas is facing a slue of problems. The question now becomes just how long will this price slide last? With Insulet's new OmniPod system hitting the market and sales of Amylin's Byetta taking off new pump placements will be hard to come by. This puts Animas in the precious situation of relying on sales of disposables and pump upgrades as their primary revenue sources. Animas also faces the prospect of falling further behind market leader MiniMed, a division of Medtronic (NYSE:MDT), when MiniMed introduces their sensor augmented pump. Finally, with Roche back in the insulin pump business the competitive environment just became that much tougher.